Research graph
References from BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer immunotherapies: a hope for the uncurable?
10.3389/fmmed.2023.1140977 · 2023 · External reference
Cancer immunology: immune escape of tumors—expression and regulation of HLA class I molecules and its role in immunotherapies
10.1097/pap.0000000000000389 · 2023 · External reference
Mutations associated with acquired resistance to PD-1 blockade in melanoma
10.1056/nejmoa1604958 · 2016 · External reference
Epigenetic regulation of tumor immunity
10.1172/jci178540 · 2024 · External reference
BET bromodomain inhibition as a therapeutic strategy to target c-myc
10.1016/j.cell.2011.08.017 · 2011 · External reference
BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1
10.1016/j.celrep.2017.02.011 · 2017 · External reference
BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma
10.1016/j.ymthe.2022.07.022 · 2022 · External reference
Stimulation of innate immunity by host and viral RNAs
10.1016/j.it.2019.10.009 · 2019 · External reference
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy
10.1172/jci131572 · 2020 · External reference
Expansion of tumor-infiltrating lymphocytes from melanoma tumors
10.1007/978-1-4939-8979-9_7 · 2019 · External reference
Cancer neoepitopes for immunotherapy: discordance between tumor-infiltrating T cell reactivity and tumor MHC peptidome display
10.3389/fimmu.2019.02766 · 2019 · External reference
Genomic classification of cutaneous melanoma
10.1016/j.cell.2015.05.044 · 2015 · External reference
Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma
10.1080/2162402x.2015.1029698 · 2015 · External reference
BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression
10.1016/j.celrep.2016.08.032 · 2016 · External reference
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
10.1186/s13045-023-01405-9 · 2023 · External reference
Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
10.1038/onc.2013.179 · 2014 · External reference
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
10.1016/j.cell.2016.02.065 · 2016 · External reference
Trim21 regulates Nmi-IFI35 complex-mediated inhibition of innate antiviral response
10.1016/j.virol.2015.08.013 · 2015 · External reference
A20 (tnfaip3) is a negative feedback regulator of RIG-I-Mediated IFN induction in teleost
10.1016/j.fsi.2018.10.082 · 2019 · External reference
Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer
10.1158/2326-6066.cir-21-0826 · 2022 · External reference
Mitochondrial antiviral signaling protein: a potential therapeutic target in renal disease
10.3389/fimmu.2023.1266461 · 2023 · External reference
Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma
10.1126/scitranslmed.abb0152 · 2020 · External reference
Innate RIG-I signaling restores antigen presentation in tumors and overcomes T cell resistance
10.15698/cst2021.02.242 · 2021 · External reference
Uncovering the tumor antigen landscape: what to know about the discovery process
10.3390/cancers12061660 · 2020 · External reference
Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity
10.1136/jitc-2021-003863 · 2022 · External reference
RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma
10.1093/jmcb/mjad001 · 2023 · External reference
RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells
10.1038/cdd.2014.96 · 2014 · External reference
Therapeutically active RIG-I agonist induces immunogenic tumor cell killing in breast cancers
10.1158/0008-5472.can-18-0730 · 2018 · External reference
Tumor immunogenic cell death as a mediator of intratumor CD8 T-cell recruitment
10.3390/cells11223672 · 2022 · External reference
Molecular characteristics of immunogenic cancer cell death
10.1038/sj.cdd.4402269 · 2008 · External reference
CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment
10.1038/s41467-022-35615-5 · 2023 · External reference
Tumor-infiltrating dendritic cell states are conserved across solid human cancers
10.1084/jem.20200264 · 2021 · External reference
Atlas of clinically distinct cell states and ecosystems across human solid tumors
10.1016/j.cell.2021.09.014 · 2021 · External reference
A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade
10.1016/j.cell.2018.09.006 · 2018 · External reference
DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation
10.1126/science.aab1433 · 2015 · External reference
MYC protein stability is negatively regulated by BRD4
10.1073/pnas.1919507117 · 2020 · External reference
Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade
10.1158/1078-0432.ccr-19-1868 · 2020 · External reference
Double-edged effects of interferons on the regulation of cancer-immunity cycle
10.1080/2162402x.2021.1929005 · 2021 · External reference
Melanoma dedifferentiation induced by interferon-gamma epigenetic remodeling in response to anti-PD-1 therapy
10.1172/jci145859 · 2021 · External reference
Achieving clinical success with BET inhibitors as anti-cancer agents
10.1038/s41416-021-01321-0 · 2021 · External reference
Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
10.1038/s41392-023-01647-6 · 2023 · External reference
BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3
10.1038/s41467-024-46778-8 · 2024 · External reference
BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells
10.1038/s41375-023-01808-0 · 2023 · External reference
